Table 3.
Cardiovascular hospitalization profiles in the propensity score matched patient cohorts for individual antiarrhythmic drugs in the AFFIRM trial
| Amiodarone | Rate | Sotalol | Rate | Class 1C | Rate | |
|---|---|---|---|---|---|---|
| CV Hosp. | 342 | 309 | 310 | 252 | 126 | 111 |
| # Fatal First CVH - no. (%) | 13 (3.8%) | 14 (4.5%) | 11(3.5%) | 5 (2.0%) | 3(2.4%) | 8(7.2%) |
| CVH < 3 d - no. (%) | 96(28.1%) | 95(30.7%) | 82(26.5%) | 70(27.8%) | 41(32.5%) | 35(31.5%) |
| CVH < 3d + CV- no. (%) | 40(11.7%) | 11(3.6%) | 35(11.3%) | 9(3.6%) | 12(9.5%) | 8(7.2%) |
| CVH<3d, CV, no ER/ICU - no. (%) |
21(6.1%) | 6(1.9%) | 19(6.1%) | 4 (1.6%) | 5(4.0%) | 1 (0.9%) |
| CVH > 3 d - no. (%) | 246(71.9%) | 214(69.3%) | 228(73.5%) | 182 (72.2%) | 85(67.5%) | 76(68.5%) |
| ICU Days First CVH- no. (%) | 95(27.8%) | 84(27.2%) | 66(21.3%) | 72 (28.6%) | 32(25.4%) | 34(30.6%) |
| Warfarin use at First CVH (% of CVH) |
279 (81.6%) |
275 (89.0%) |
273 (88.1%) |
227 (90.1%) |
108 (85.7%) |
101 (91.0%) |
| Bleeds/stroke/embolic events(% of CVH) |
42 (12.3%) |
54 (17.5%) |
28 (9.1%) |
40 (15.9%) |
13 (14.1%) |
18 (16.2%) |
| Warfarin use at above Event (% of event) |
31 (73.8%) |
47 (87.0%) |
17 (60.7%) |
31 (77.5%) |
12 (67.7%) |
7 (50.0%) |
Abbreviations: CV – cardiovascular; CVH – Cardiovascular hospitalization; ER – emergency room visit; ICU – intensive care unit stay;